David Charles Lubner Acquires 55,555 Shares of Braveheart Bio (NASDAQ:BRVE) Stock

Braveheart Bio, Inc. (NASDAQ:BRVE) Director David Charles Lubner bought 55,555 shares of the firm’s stock in a transaction on Friday, August 7th. The stock was bought at an average cost of $18.00 per share, for a total transaction of $999,990.00. Following the transaction, the director directly owned 55,555 shares of the company’s stock, valued at $999,990. The trade was a ∞ increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Braveheart Bio Trading Up 0.7%

Shares of BRVE stock opened at $30.00 on Friday. Braveheart Bio, Inc. has a 1-year low of $28.47 and a 1-year high of $32.00.

Braveheart Bio Company Profile

We are a clinical‑stage biopharmaceutical company focused on developing therapies for patients with hypertrophic cardiomyopathy (“HCM”) and other serious cardiovascular diseases. Our lead product candidate, BHB‑1893, is a next-generation oral small‑molecule cardiac myosin inhibitor (“CMI”), that we are developing for the treatment of obstructive HCM (“oHCM”) and non‑obstructive HCM (“nHCM”). Our goal is to improve the treatment options for these patients by enhancing speed of onset, depth of gradient response, systolic safety, and reversibility, and reducing prescribing complexity.